WGS Analysis of COVID-19 Positive Patients

Vanda Pharmaceuticals

Status: Completed

Conditions: COVID-19; Coronavirus Infection

Study type: Observational

Funder types: Industry

Identifiers

NCT04353401

VP-01-01

CALYPSO

Details and patient eligibility

About

We aim to better understand the mode of action of COVID-19 in the context of its interaction with the host genome through whole-genome sequencing.

Enrollment: 79 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Ability and acceptance to provide written informed consent and fluent in English.
• Men or women between 18-100+ years, inclusive.
• Willing to comply with study procedures.
• SARS-CoV-2 positive test result as confirmed by a RT-PCR assay with a sputum or nasopharyngeal sample (either done prior to or at the screening visit).